Prof. Ronit Satchi-Fainaro received her B.Pharm. from the Hebrew University (1995) and her Ph.D. in Polymer Chemistry and Cancer Nanomedicine from the University of London (1999). She was a Postdoctoral Research Fellow at Harvard University and Children’s Hospital Boston working with Prof. Judah Folkman on Vascular and Cancer Biology. She joined Tel Aviv University in 2006 and serves on the Board of Directors of Teva Pharmaceutical Industries, Board of Governors of Tel Aviv University, Member of 8400- The Health network, member of the Scientific Advisory Board of several research institutes, hospitals, venture capital, biotech companies and editorial boards of scientific journals.

Her multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from cancer dormancy leading to the discovery of new molecular targets to interrupt tumor-host interactions. Her approach is followed by the design of highly-selective targeting molecules integrating biology, chemistry, medicine, bioinformatics and nanotechnology to selectively guide drugs into pathological sites. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. She is a founder of 2 spin-off companies and is actively engaged in translational research with several industry partners and in science outreach. She was awarded 3 European Research Council (ERC) research grants, and numerous prestigious grants and prizes among them Teva Pharmaceutical Industries Founders Award for the Discovery of new molecular mechanisms and targets that would lead to new therapeutic approaches, The 2020 Youdim Family Prize for Excellence in Cancer Research, The 2020 Kadar Family Award for Outstanding Research, the 2020 Michael Bruno Memorial Award and the 2020 Humboldt Foundation Bessel Research Prize.